Muscle Damage of the TFL (Tensor Fascia Latae) During Total Hip Arthroplasty (THA) Through Direct Anterior Approach (DAA) (TFL)

January 14, 2026 updated by: University Hospital, Bordeaux

Muscle Damage of the TFL (Tensor Fascia Latae) During Total Hip Arthroplasty (THA) Through Direct Anterior Approach (DAA), Evaluation of the Correlation With Short Term Functional Results

Direct Anterior Approach (DAA) is known to cause damage to the TFL during the surgical approach, the point of this study is to evaluate the impact between the severity of the per operative TFL damage and the functional short term results.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Total hip arthroplasty is one of the most frequent surgical procedure and it has changed the approach of hip arthrosis. There are a few surgical approaches frequently used : posterolateral approach, anterolateral approach and the direct anterior approach. It has been previously shown that the DAA is causing less muscle damage than the other surgical approaches, the anterior interval is considered as internervous and intermuscular muscle-sparing technique. However, several reports have proved that the DAA was also associated with muscle damage, particularly to the tensor fascia lata during the exposition with the instruments.

The purpose of this study is to determinate the correlation between the severity of muscle damage during surgery and the functional post operative short and medium term results. We underwent grading visible muscle damage during surgery after implant positioning by a grading system in 5 stages from 0 (intact or a few fibers) to 4 (more than 75% of muscle damage). Functional results were established by Harris Hip Score at 6 weeks and 6 months follow up.

Study Type

Interventional

Enrollment (Estimated)

150

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • adult (>18 years old),
  • patient undergoing primary Total Hip Arthroplasty through Direct Anterior Approach for osteoarthritis

Exclusion Criteria:

  • hip dysplasia
  • leg length discrepancy greater than 2cm
  • history of homolateral hip surgery
  • neuromuscular pathology
  • patients declining the protocol

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Usual surgical procedure
Patient with usual surgical procedure : Total Hip Arthroplasty through Direct Anterior Approach
Other: Data collection and self-administered questionnaire
Data collection and self-administered questionnaire (HHS and SF-36)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Correlation between post operative functional results and TFL muscle damage
Time Frame: week 6

Correlation between :

  • short term post operative functional results, evaluated by Harris Hip score at 6 weeks. Harris Hip score has 10 items with several propositions per each item and total score from 2 to 100 , and
  • TFL muscle damage grade during surgery evaluated with ATHLAS classification : score 0 (intact or few fibres), 1 (0-25% of fibres), 2 (25-50%), 3 (50-75%) et 4 (>75%)
week 6

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Harris Hip score 6 months
Time Frame: 6 months
Result of Harris Hip score at 6 months Harris Hip score has 10 items with several propositions per each item and total score from 2 to 100 ,
6 months
Quality of life scale
Time Frame: 6 weeks, 6 months
Evolution of SF-36 questionnaire score between 6 weeks and 6 months after total hip arthroplasty
6 weeks, 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Bordeaux

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

February 1, 2026

Primary Completion (Estimated)

April 1, 2026

Study Completion (Estimated)

October 1, 2026

Study Registration Dates

First Submitted

January 14, 2026

First Submitted That Met QC Criteria

January 14, 2026

First Posted (Actual)

January 22, 2026

Study Record Updates

Last Update Posted (Actual)

January 22, 2026

Last Update Submitted That Met QC Criteria

January 14, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CHUBX 2024/83

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Arthroplasty

Clinical Trials on Data collection and self-administered questionnaire

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe